Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ:LABT)SARASOTA, FL, UNITED STATES, October 2, 2026 /EINPresswire.com/ --
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ:LABT)
SARASOTA, FL, UNITED STATES, October 2, 2026 /EINPresswire.com/ — Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the “Company”), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.
Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company’s in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1
Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City. He will also attend and present at the ThinkEquity Conference on October 15, 2026, in New York City. Later in the month, Dr. Cooper will present a poster on Nu-3 preclinical data at IDWeek on October 22, 2026, in Washington, D.C.
Details are as follows:
Event: Maxim Growth Summit
Date: October 13-14, 2026
Location: Hard Rock Hotel, New York City
Event: ThinkEquity Conference
Date: October 15, 2026
Location: The Mandarin Oriental Hotel, New York City
Presentation: Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In- Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers.
Presentation Time: 3:30 pm
Event: IDWeek
Date: October 21-24, 2026
Location: Walter E. Washington Convention Center, Washington, D.C. (Hybrid Format Available)
The conferences provide opportunities for Lakewood-Amedex to engage with members of the investment, biotechnology, and infectious disease communities and highlight the Company’s ongoing development programs Bisphosphocin® antimicrobial technology.
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class – to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Contacts:
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Michelle Katsel
(201) 790-3390
mkatsel@tiberend.com
Additional Contact
David Shapiro
B2i Digital, Inc.
+1 212-579-4844
david@b2idigital.com
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Other
LABT CEO Kelvin Cooper heads to three October conferences, including Nu-3 presentations.
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
